Physician profile
Pranjal Jain
NPI 1730408121
$4,700.71
in general payments reported to CMS, 2019-2025
30 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $86.66 · 2021: $382 · 2022: $304 · 2023: $693 · 2024: $1,941 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,875 · Travel and Lodging: $855 · Education: $20.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,875.22 |
| Travel and Lodging | $855.01 |
| Education | $20.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $1,437.96 | 2019-2024 | Renal - Acute |
| One Lambda, INC. | $296.92 | 2025 | |
| Mallinckrodt Hospital Products INC. | $252.57 | 2020-2025 | Terlivaz, Acthar |
| Outset Medical INC | $244.06 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $213.87 | 2022-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $191.31 | 2019-2023 | Krystexxa |
| Apellis Pharmaceuticals, INC. | $178.22 | 2025 | Empaveli |
| Aurinia Pharma U.S., INC. | $176.69 | 2022-2025 | Lupkynis |
| Novo Nordisk INC | $172.45 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $169.11 | 2021-2025 | |
| Cormedix INC. | $167.50 | 2024 | Defencath |
| Novartis Pharmaceuticals Corporation | $154.05 | 2023-2025 | |
| Nxstage Medical, INC. | $126.67 | 2024 | |
| Alexion Pharmaceuticals, INC. | $125.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $125.00 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $124.16 | 2023-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $96.48 | 2021-2024 | Jynarque |
| Opko Pharmaceuticals, LLC | $85.34 | 2020-2024 | Rayaldee |
| Glaxosmithkline, LLC. | $77.46 | 2022-2025 | Benlysta |
| Lilly USA, LLC | $50.56 | 2023-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.20 | 2025 | Jardiance |
| Daiichi Sankyo INC. | $31.42 | 2019-2021 | |
| Ardelyx, INC. | $28.89 | 2025 | Ibsrela |
| Bard Peripheral Vascular, INC. | $24.09 | 2019 | |
| Akebia Therapeutics INC | $20.25 | 2022 | |
| Cycle Pharmaceuticals INC | $18.67 | 2025 | Venxxiva |
| Scpharmaceuticals INC. | $18.26 | 2025 | |
| Alnylam Pharmaceuticals INC. | $16.95 | 2024 | Givlaari |
| Veloxis Pharmaceuticals, INC. | $16.70 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranjal Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.